Medical Therapy. Efficacy or Lack of Efficacy

Cyclopamine Attenuates Pulmonary Arterial Hypertension Development: Implications of Hedgehog Signaling Involvement for the Pathophysiology

Makito Sakurai, Susumu Hosakawa, Yohei Yamaguchi, Susumu Kirimura, Kensuke Ihara, Kenichi Ohashi, Tetsushi Furukawa, Tetsuo Sasano, Kenichi Kashimada, Taku IshiiInstitute of Science Tokyo. Japanese Red Cross Musashino Hospital.  National Center for Child Health and Development. Japan Federation of American Societies for Experimental Biology JournalFASEB J 2025; 39: DOI: 10.1096/fj.202403350R AbstractPulmonary arterial hypertension (PAH) is one of […]

Cyclopamine Attenuates Pulmonary Arterial Hypertension Development: Implications of Hedgehog Signaling Involvement for the Pathophysiology Read More »

Role of phosphodiesterase-3 inhibitor in cardiorespiratory fitness and functional class of patients with pulmonary hypertension: A randomized, double-blind, placebo-controlled trial

Sefri N. Sofia, Udin Bahrudin, Ilham Uddin, Muhammad A. Sobirin, Erna Setiawati, Galuh Hardaningsih, Kevin C. Tjandra, Edward K. S. LimijadiUniversitas Diponegoro. Dr. Kariadi Hospital. Indonesia Narra JNarra J 2025; 5: DOI: 10.52225/narra.v5i1.1301 AbstractMany patients with acyanotic shunt congenital heart disease (CHD) are diagnosed only in adulthood, by which time pulmonary hypertension (PH) has developed, impairing

Role of phosphodiesterase-3 inhibitor in cardiorespiratory fitness and functional class of patients with pulmonary hypertension: A randomized, double-blind, placebo-controlled trial Read More »

Inhibiting Serotonin Synthesis for the Treatment of Pulmonary Arterial Hypertension

Georg Hansmann, Michael BaderFriedrich-Alexander-University Erlangen-Nürnberg. Trypto Therapeutics. Charité-Universitätsmedizin. University of LübeckGermany Pulmonary CirculationPulm Circ 2025; 15: DOI: 10.1002/pul2.70100 AbstractAbstract Not Available CategoryMedical Therapy. Efficacy or Lack of EfficacyMedical Therapy. Adverse Effects or Lack of Adverse Effects Age Focus: No Age-Related Focus Fresh or Filed Publication: Filed (PHiled). Greater than 1-2 years since publication Article Access Free

Inhibiting Serotonin Synthesis for the Treatment of Pulmonary Arterial Hypertension Read More »

Comparative study between nebulized and intravenous magnesium sulfate for treatment of persistent pulmonary hypertension in neonates

Nashwa Farouk Mohamed, Osama Abu El Fetouch Zaki El Feky, Heba Morsy Saad El Din El Ganady, Walid Abd Elatif Abd El HalimBenha University.Egypt Journal of Neonatal-Perinatal MedicineJ Neonatal Perinatal Med 2025; 18: 246-254DOI: 10.1177/19345798251325510 AbstractBackground: Persistent pulmonary hypertension of the newborn (PPHN) is a life-threatening condition resulting from elevated pulmonary vascular resistance, causing severe hypoxemia.

Comparative study between nebulized and intravenous magnesium sulfate for treatment of persistent pulmonary hypertension in neonates Read More »

Persistent pulmonary hypertension of the newborn infant (PPHN) due to premature closure of the ductus arteriosus (DA)

Ayevbekpen Grace Okoye, Adrita Khawash, Mahesh Nanjundappa, Matthew Jones, Anne GreenoughKings College Hospital NHS Foundation Trust. Evelina Children’s Hospital and Guys and St Thomas Hospital. United Kingdom Case Reports in Perinatal MedicineCase Rep Perinat Med 2025; 13: DOI: 10.1515/crpm-2024-0001 AbstractObjectives: To describe the course of an infant with persistent pulmonary hypertension of the newborn (PPHN) secondary to

Persistent pulmonary hypertension of the newborn infant (PPHN) due to premature closure of the ductus arteriosus (DA) Read More »

Mechanism and Treatment of Right Ventricular Failure Due to Pulmonary Hypertension in Children

Bibhuti B. DasUniversity of Mississippi Medical Center.United States ChildrenChildren 2025; 12: DOI: 10.3390/children12040476 AbstractPulmonary hypertension (PH) is a progressive disorder characterized by obstructive changes in the pulmonary vasculature, leading to increased pulmonary vascular resistance (PVR), right ventricular (RV) strain, and eventual RV failure (RVF). Despite advancements in medical therapy, PH remains associated with significant morbidity and

Mechanism and Treatment of Right Ventricular Failure Due to Pulmonary Hypertension in Children Read More »

Different Effects of Riociguat and Vericiguat on Pulmonary Vessels and Airways

Katharina Nubbemeyer, Julia Krabbe, Svenja Böll, Anna Michely, Sebastian Kalverkamp, Jan Spillner, Christian MartinRWTH Aachen University. Ruhr University Bochum. Germany BiomedicinesBiomedicines 2025; 13: DOI: 10.3390/biomedicines13040856 AbstractBackground/Objectives: Pulmonary hypertension is a progressive disease leading to right heart failure. One treatment strategy is to induce vasodilation via the nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate (NO-sGC-cGMP) signaling pathway. There

Different Effects of Riociguat and Vericiguat on Pulmonary Vessels and Airways Read More »

Successful Treatment of Congenital Chylothorax by Early Use of Prednisolone: A Case Report

Kyoka Hirano , Koji Nakae , Manaka Matsunaga , Kentaro Ueno , Yasuhiro OkamotoKagoshima University Hospital.Japan CureusCureus 2024; 16:DOI: 10.7759/cureus.60628 AbstractCongenital chylothorax is the most common form of pleural effusion during the neonatal period; however, no treatment strategy exists. The pathogenesis and etiology of this disease are not fully understood; hence, several cases are difficult to

Successful Treatment of Congenital Chylothorax by Early Use of Prednisolone: A Case Report Read More »

Mas1 Receptor Activation is Necessary and Sufficient to Transduce ACE2 Effect in PAH, But Ang(1-7) Alone is Insufficient

James West, Megha Talati, Erica Carrier, Anandharajan Rathinasabapathy, Ibragim Gaidarov, Benjamin Vigl, Ying Cai, Hongpeng Jia, Tom Blackwell, Santhi Gladson, Christie Moore, Sheila Shay, Ethan Sevier, Anna HemnesVanderbilt University Medical Center. Eurofins Beacon Discovery. Alterras Therapeutics. Johns Hopkins University School of Medicine.United States and Austria Pulmonary CirculationPulm Circ 2025; 15: DOI: 10.1002/pul2.70083 AbstractACE2 has shown effectiveness

Mas1 Receptor Activation is Necessary and Sufficient to Transduce ACE2 Effect in PAH, But Ang(1-7) Alone is Insufficient Read More »

The sonic hedgehog signaling inhibitor cyclopamine improves pulmonary arterial hypertension via regulating the bone morphogenetic protein receptor 2 pathway

Youpeng Jin, Fei Mao, Xuehui Wang, Jie Zhang, Yanting Gao, Youfei FanShandong Provincial Hospital, First Affiliated Hospital and Shandong First Medical University.China Scientific ReportsSci Rep 2025; 15: DOI: 10.1038/s41598-025-97627-7 AbstractPulmonary arterial hypertension (PAH) is a severe and progressive disease with hallmarks of pulmonary vascular remodeling and bone morphogenetic protein receptor 2 (BMPR2) mutation. Recent studies indicate

The sonic hedgehog signaling inhibitor cyclopamine improves pulmonary arterial hypertension via regulating the bone morphogenetic protein receptor 2 pathway Read More »

Scroll to Top